# Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2019

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2020-01-08
- Accepted by EDGAR: Jan 8, 2020, 14:39 ET
- Period: 2019-11-30
- Accession: 0001275187-20-000005
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000127518720000005/ango-113019x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000127518720000005/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-11-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-09-01 to 2019-11-30 | $70.0m | us-gaap:Revenues |
| Revenue | 6 months, 2019-06-01 to 2019-11-30 | $136.0m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-09-01 to 2019-11-30 | $28.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2019-06-01 to 2019-11-30 | $56.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-09-01 to 2019-11-30 | $41.5m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2019-06-01 to 2019-11-30 | $79.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-09-01 to 2019-11-30 | $7.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-06-01 to 2019-11-30 | $14.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-09-01 to 2019-11-30 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-06-01 to 2019-11-30 | −$4.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-09-01 to 2019-11-30 | $41.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2019-06-01 to 2019-11-30 | $506.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-09-01 to 2019-11-30 | −$566.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2019-06-01 to 2019-11-30 | −$682.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-09-01 to 2019-11-30 | −$2.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-06-01 to 2019-11-30 | −$4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-09-01 to 2019-11-30 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2019-06-01 to 2019-11-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-09-01 to 2019-11-30 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2019-06-01 to 2019-11-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-09-01 to 2019-11-30 | 37,992,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2019-06-01 to 2019-11-30 | 37,887,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2019-06-01 to 2019-11-30 | −$597.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2019-06-01 to 2019-11-30 | $4.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-11-30 | $41.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-11-30 | $132.0m | us-gaap:AssetsCurrent |
| Total assets | at 2019-11-30 | $724.9m | us-gaap:Assets |
| Current liabilities | at 2019-11-30 | $57.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-11-30 | $111.1m | us-gaap:Liabilities |
| Current portion of debt | at 2019-11-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2019-11-30 | $613.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 36,985 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### EXECUTIVE OVERVIEW

### Company and Market

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical device; and fluctuations in the global economy.

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and business development opportunities and feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.

We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of a direct sales and distributor relationships. We expect our businesses to grow in both sales and profitability through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.

On October 2, 2019, the Company entered into a share purchase agreement to acquire Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology. The aggregate purchase price of $60.7 million included an upfront payment of $45.8 million and contingent consideration with an estimated fair value of $14.9 million. This acquisition expands and complements the Company’s Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease.

On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the “Divestiture”) and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. (“Medline”) pursuant to an asset purchase agreement dated April 17, 2019 (the “Asset Purchase Agreement”). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was $169.2 million in cash and resulted in a gain of $46.6 million after working capital adjustments of $0.6 million. A portion of the net proceeds were used on June 3, 2019 to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business.

In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and six months ended November 30, 2019 compared to the three and six months ended November 30, 2018 follows:

Three months ended November 30, 2019:

- Revenue was consistent with the prior year quarter to date
- Gross margin increased 140 bps to 59.3%
- Operating loss increased by $0.9 million to $3.4 million
- Loss per share from continuing operations improved by $0.03 to a loss of $0.07

Six months ended November 30, 2019:

- Revenue increased by 1.6% to $136.0 million
- Gross margin increased 150 bps to 58.6%
- Operating loss decreased by $4.4 million to $4.3 million
- Loss per share from continuing operations improved by $0.14 to a loss of $0.11

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 18 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

### Results of Operations for the Three Months Ended November 30, 2019 and 2018

For the three months ended November 30, 2019, the Company reported net loss of $2.7 million, or $0.07 per diluted share, on net sales of $70.0 million, compared with net loss of $3.6 million, or $0.10 loss per diluted share, on net sales of $70.0 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts and returns.

Net sales for the three months ended November 30, 2019 and 2018:

*(in thousands)*

| Net Sales by Global Business Unit | Three months ended Nov 30, 2019 | Nov 30, 2018 | % Growth |
| --- | ---: | ---: | ---: |
| Vascular Interventions & Therapies | $31,150 | $30,976 | 0.6% |
| Vascular Access | 22,784 | 23,723 | (4.0)% |
| Oncology | 16,069 | 15,286 | 5.1% |
| Total | $70,003 | $69,985 | 0.0% |
| Net Sales by Geography |  |  |  |
| United States | $55,555 | $56,300 | (1.3)% |
| International | 14,448 | 13,685 | 5.6% |
| Total | $70,003 | $69,985 | 0.0% |

For the three months ended November 30, 2019, net sales were consistent with the same period in the prior year.

#### Vascular Interventions & Therapies

- Total Vascular Interventions & Therapies sales increased $0.2 million primarily attributable to strong performance in the AngioVac business which grew $1.7 million and in Core Peripheral products which grew $0.4 million year over year. The Company continues to see strong case volumes in AngioVac, which increased 31% from the prior year due to increased adoption of the Company's unique technology and the launch of the next generation of the AngioVac product. These increases were partially offset by the termination of the Asclera distribution agreement, which contributed $1.7 million of revenue in the prior year.
- U.S. Vascular Interventions & Therapies sales increased $0.4 million due to increased case volume in AngioVac and increased Core Peripheral product sales which was partially offset by the termination of the Asclera distribution agreement, which contributed $1.7 million of revenue in the prior year.
- International Vascular Interventions & Therapies sales decreased $0.2 million.

#### Vascular Access

- Total Vascular Access sales decreased $0.9 million due to decreases in PICCs and Ports partially offset by growth in the Dialysis business of $0.1 million. BioFlo product lines comprise 52% of overall Vascular Access sales compared to 50% a year ago.
- U.S. Vascular Access sales decreased by $1.5 million due to competitive pressures in the PICC product lines and lower Port sales. This was partially offset by growth in Dialysis products which continue to gain traction in the marketplace.
- International Vascular Access sales increased by $0.6 million as the Company continues to expand its global reach of its Vascular Access product offerings.

#### Oncology

- Total Oncology sales increased $0.8 million year over year primarily due to increased NanoKnife capital sales of $1.9 million and $0.3 million in increased sales of balloons. This was partially offset by decreased sales of Radiofrequency Ablation and NanoKnife disposable sales.
- U.S. Oncology sales increased by $0.3 million, driven by NanoKnife capital sales of $1.6 million and balloons of $1.6 million. This was partially offset by a decrease in RadioFrequency Ablation and NanoKnife disposable sales.
- International Oncology sales increased by $0.5 million year over year as a result of increased NanoKnife capital sales of $0.9 million. This was partially offset by decreased NanoKnife disposable and RadioFrequency and Microwave Ablation product sales.

### Gross Profit, Operating expenses, and Other income (expense)

*(in thousands)*

|  | Three months ended Nov 30, 2019 | Nov 30, 2018 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $41,544 | $40,552 | 2.4% |
| Gross profit % of sales | 59.3% | 57.9% |  |
| Research and development | $7,764 | $7,076 | 9.7% |
| % of sales | 11.1% | 10.1% |  |
| Selling and marketing | $20,113 | $19,263 | 4.4% |
| % of sales | 28.7% | 27.5% |  |
| General and administrative | $10,994 | $9,262 | 18.7% |
| % of sales | 15.7% | 13.2% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $1.0 million compared to the prior year. The increase is primarily attributable to the following:

- Sales volume and mix driven by AngioVac and NanoKnife capital sales positively contributed $1.5 million year over year.
- Net productivity contributed $0.4 million of favorability driven by purchase price variances.
- Favorable freight expense contributed $0.3 million.
- Currency and pricing headwinds negatively impacted gross margin by $0.1 million year over year, primarily driven by pricing.
- The termination of the Asclera distribution agreement negatively impacted gross margin by $1.0 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased $0.7 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increased approximately $0.5 million due to increased variable compensation along with increased headcount as a result of the Eximo acquisition.
- Increased project spend contributed $0.3 million of additional expense.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased $0.9 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately $0.8 million which is primarily attributed to increased variable compensation and increased commissions as a result of NanoKnife capital sales during the second quarter.
- Other sales and marketing expenses increased $0.2 million to support company-wide initiatives.
- Outside service fees decreased $0.2 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased $1.7 million compared to the prior year. The increase is primarily attributable to the following:

- Legal and professional fees relating to ongoing litigation that is within the normal course of business increased $1.5 million.
- Outside consultant spend increased $0.2 million.
- Compensation and benefits decreased approximately $0.2 million primarily as a result of the timing of fully vested stock based compensation awards and lower high cost benefit claims.

*(in thousands)*

|  | Three months ended Nov 30, 2019 | Nov 30, 2018 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $4,530 | $4,506 | $24 |
| Change in fair value of contingent consideration | $145 | $244 | $(99) |
| Acquisition, restructuring and other items, net | $1,421 | $2,728 | $(1,307) |
| Other expense | $121 | $(1,250) | $1,371 |

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- Amortization expense remained consistent with the prior year. The addition of the Eximo product technology intangible asset increased intangible assets by $59.0 million and resulted in additional amortization expense of $0.7 million. This was partially offset by the write-off of the Merz intangible in the fourth quarter of fiscal year 2019 and other intangibles that became fully amortized.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The change from the prior year is due to decreased amortization on the RadiaDyne contingent consideration as a result of the gain of $8.4 million that was recorded in the fourth quarter of fiscal year 2019 and the gain of $0.6 million that was recorded in the first quarter of fiscal year 2020. The Eximo contingent consideration was recorded for $14.9 million in the second quarter of fiscal year 2020. In addition, the final minimum payment of $1.2 million was paid for the Microsulis contingent consideration during the first quarter of fiscal 2020.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $1.3 million compared to the prior year. The decrease is primarily attributable to the following:

- M&A expense of $0.4 million was incurred in the second quarter of fiscal year 2020 compared to $1.5 million in the prior year.
- Legal expense, related to litigation that is outside of the normal course of business, of $0.7 million was recorded in the second quarter of fiscal year 2020 compared to $0.9 million in the prior year.
- In the second quarter of fiscal year 2020, the Company incurred $0.7 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business.
- As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline $0.6 million in the second quarter of fiscal year 2020.
- Other expenses of $0.3 million in the second quarter of fiscal year 2020 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business.

Other expenses, net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The decrease in other expenses from the prior year of $1.4 million is due to decreased interest expense of $1.2 million as the Credit Facility was paid down in full at the beginning of the first quarter of fiscal year 2020. In addition to the decrease in interest expense, interest income increased $0.1 million from the prior year as a result of increased cash due to proceeds from the sale of the Fluid Management business.

### Income Tax Provision (Benefit)

*(in thousands)*

|  | Three months ended Nov 30, 2019 | Nov 30, 2018 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $(0.6) | $(0.2) |
| Effective tax rate including discrete items | 17.1% | 5.0% |

Our effective tax rate including discrete items for the three month periods ended November 30, 2019 and 2018 was 17.1% and 5.0%, respectively. In fiscal 2020, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock based compensation).

The estimated annual effective tax rate, however, prior to discrete items was 13.2% in the second quarter of fiscal 2020, as compared to 13.2% for the same period in fiscal 2019.

### Results of Operations for the Six Months Ended November 30, 2019 and 2018

For the six months ended November 30, 2019, the Company reported net loss of $4.0 million, or $0.11 per diluted share, on net sales of $136.0 million, compared with net loss of $9.3 million, or $0.25 loss per diluted share, on net sales of $133.9 million during the same quarter of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts and returns.

Net sales for the six months ended November 30, 2019 and 2018:

*(in thousands)*

| Net Sales by Global Business Unit | Six months ended Nov 30, 2019 | Nov 30, 2018 | % Growth |
| --- | ---: | ---: | ---: |
| Vascular Interventions & Therapies | $60,063 | $59,573 | 0.8% |
| Vascular Access | 45,943 | 47,513 | (3.3)% |
| Oncology | 30,039 | 26,842 | 11.9% |
| Total | $136,045 | $133,928 | 1.6% |
| Net Sales by Geography |  |  |  |
| United States | $108,492 | $107,796 | 0.6% |
| International | 27,553 | 26,132 | 5.4% |
| Total | $136,045 | $133,928 | 1.6% |

For the six months ended November 30, 2019, net sales increased $2.1 million to $136.0 million compared to the same period in the prior year.

#### Vascular Interventions & Therapies

- Total Vascular Interventions & Therapies sales increased $0.5 million primarily attributable to strong performance in the AngioVac business which grew $2.7 million and in Core Peripheral products which grew $0.3 million year over year. The Company continues to see strong case volumes in AngioVac, which increased 33% from the prior year due to increased adoption of the Company's unique technology and the launch of the next generation of the AngioVac product. These increases were partially offset by the termination of the Asclera distribution agreement, which contributed $3.1 million of revenue in the prior year.
- U.S. Vascular Interventions & Therapies sales increased $0.2 million due to increased case volume in AngioVac and increased Core Peripheral product sales which were partially offset by the termination of the Asclera distribution agreement, which contributed $3.1 million of revenue in the prior year.
- International Vascular Interventions & Therapies sales increased $0.3 million due to increased volume in Angiographic catheters primarily in EMEA (Europe, the Middle East and Africa).

#### Vascular Access

- Total Vascular Access sales decreased $1.6 million due to decreases in PICCs and Ports partially offset by growth in the Dialysis business of $0.6 million. BioFlo product lines comprise 51% of overall Vascular Access sales compared to 50% a year ago.
- U.S. Vascular Access sales decreased by $2.7 million due to competitive pressures in the PICC product lines and lower Port sales. This was partially offset by growth in Dialysis products which continue to gain traction in the marketplace.
- International Vascular Access sales increased by $1.1 million as the Company continues to expand its global reach of its Vascular Access product offerings.

#### Oncology

- Total Oncology sales increased $3.2 million year over year primarily due to increased NanoKnife capital sales of $2.8 million along with $2.1 million and $0.9 million in increased sales of balloons and BioSentry products, respectively. This was partially offset by decreased sales of Radiofrequency Ablation and NanoKnife disposable sales.
- U.S. Oncology sales increased by $3.1 million, driven by NanoKnife capital sales of $1.3 million, balloon sales of $2.1 million and BioSentry sales of $0.8 million. This was partially offset by a decrease in RadioFrequency Ablation and NanoKnife disposable sales.
- International Oncology sales increased by $0.1 million year over year as a result of increased NanoKnife capital sales of $1.5 million. This was offset by decreased NanoKnife disposable and RadioFrequency and Microwave Ablation product sales.

### Gross Profit, Operating expenses, and Other income (expense)

*(in thousands)*

|  | Six months ended Nov 30, 2019 | Nov 30, 2018 | % Change |
| --- | ---: | ---: | ---: |
| Gross profit | $79,761 | $76,505 | 4.3% |
| Gross profit % of sales | 58.6% | 57.1% |  |
| Research and development | $14,055 | $14,450 | (2.7)% |
| % of sales | 10.3% | 10.8% |  |
| Selling and marketing | $39,493 | $37,669 | 4.8% |
| % of sales | 29.0% | 28.1% |  |
| General and administrative | $19,448 | $17,697 | 9.9% |
| % of sales | 14.3% | 13.2% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $3.3 million compared to the prior year. The increase is primarily attributable to the following:

- Sales volume and mix driven by AngioVac and NanoKnife capital sales positively contributed $3.2 million year over year.

Net productivity contributed $1.1 million of favorability.

- Currency and pricing tailwinds positively impacted gross margin by $0.8 million year over year, primarily driven by pricing.
- The termination of the Asclera distribution agreement negatively impacted gross margin by $1.8 million.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense decreased $0.4 million compared to the prior year. The decrease is primarily attributable to the following:

- Compensation and benefits increased approximately $0.3 million due to increased variable compensation along with increased headcount as a result of the Eximo acquisition.
- Other R&D expenses, including facilities, samples and project initiatives timing resulted in a decrease of $0.8 million.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased $1.8 million compared to the prior year. The increase is primarily attributable to the following:

- Compensation and benefits increase of approximately $1.5 million which is primarily attributed to increased variable compensation and increased commissions as a result of NanoKnife capital sales during the second quarter.
- Other sales and marketing expenses increased $0.3 million to support company-wide initiatives.
- Outside service fees decreased $0.2 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased $1.7 million compared to the prior year. The increase is primarily attributable to the following:

- Legal and professional fees relating to ongoing litigation that is within the normal course of business increased $1.9 million.
- Outside consultant spend increased $0.3 million and other expenses increased $0.4 million.
- Compensation and benefits decreased approximately $0.8 million primarily as a result of the timing of fully vested stock based compensation awards and lower high cost benefit claims.

*(in thousands)*

|  | Six months ended Nov 30, 2019 | Nov 30, 2018 | $ Change |
| --- | ---: | ---: | ---: |
| Amortization of intangibles | $8,398 | $7,939 | $459 |
| Change in fair value of contingent consideration | $(303) | $256 | $(559) |
| Acquisition, restructuring and other items, net | $2,921 | $7,150 | $(4,229) |
| Other expense | $(442) | $(2,053) | $1,611 |

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- The increase in amortization expense from the prior year is due to intangible asset additions as a result of the Eximo product technology intangible asset which increased intangible assets by $59.0 million and resulted in additional amortization expense of $0.7 million. This was partially offset by the write-off of the Merz intangible in the fourth quarter of fiscal year 2019 and other intangibles that became fully amortized.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The change from the prior year is due to the gain of $0.6 million that was recorded on the technical milestones for the RadiaDyne contingent consideration in the first quarter of fiscal year 2020. The gain was partially offset by decreased amortization on the RadiaDyne contingent consideration as a result of the first quarter gain along with the $8.4 million gain that was recorded in the fourth quarter of fiscal year 2019. The Eximo contingent consideration was recorded for

$14.9 million in the second quarter of fiscal year 2020. In addition, the final minimum payment of $1.2 million was paid for the Microsulis contingent consideration during the first quarter of fiscal 2020.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $4.2 million compared to the prior year. The decrease is primarily attributable to the following:

- M&A expense of $0.6 million was incurred in fiscal year 2020 compared to $2.9 million in the prior year.
- Legal expense, related to litigation that is outside of the normal course of business, of $1.4 million was recorded in fiscal year 2020, which includes an offset of $0.4 million from the Biolitec bankruptcy settlement, compared to $3.7 million in the prior year.
- In fiscal year 2020, the Company incurred $1.5 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business.
- As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline $1.3 million in fiscal year 2020.
- Other expenses of $0.8 million in fiscal year 2020 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business.

Other expenses, net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The decrease in other expenses from the prior year of $1.6 million is due to decreased interest expense of $2.1 million as the Credit Facility was paid down in full at the beginning of the first quarter of fiscal year 2020. In addition to the decrease in interest expense, interest income increased $0.3 million from the prior year as a result of increased cash due to proceeds from the sale of the Fluid Management business. These increases are partially offset by the write-off of the deferred financing fees that were associated with the old Credit Facility of $0.6 million. Other expenses also include foreign currency fluctuations which increased by $0.3 million.

### Income Tax Provision (Benefit)

*(in thousands)*

|  | Six months ended Nov 30, 2019 | Nov 30, 2018 |
| --- | ---: | ---: |
| Income tax expense (benefit) | $(0.7) | $(1.4) |
| Effective tax rate including discrete items | 14.5% | 13.2% |

Our effective tax rate including discrete items for the six month periods ended November 30, 2019 and 2018 was 14.5% and 13.2%, respectively. In fiscal 2020, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock based compensation).

The estimated annual effective tax rate, however, prior to discrete items was 13.2% in the second quarter of fiscal 2020, as compared to 13.2% for the same period in fiscal 2019.

### Liquidity and Capital Resources

Our cash and cash equivalents totaled $41.2 million as of November 30, 2019, compared with $227.6 million as of May 31, 2019. As of November 30, 2019 there was no principal debt outstanding and as of May 31, 2019 there was $132.5 million principal debt outstanding. The fair value of contingent consideration liability as of November 30, 2019 and May 31, 2019, was $26.9 million and $13.5 million, respectively.

The table below summarizes our cash flows for the six months ended November 30, 2019 and 2018:

*(in thousands)*

| Cash used in: | Six Months Ended Nov 30, 2019 | Nov 30, 2018 |
| --- | ---: | ---: |
| Operating activities | $(597) | $4,086 |
| Investing activities | (50,124) | (86,336) |
| Financing activities | (135,749) | 51,254 |
| Effect of exchange rate changes on cash and cash equivalents | 76 | (280) |
| Net change in cash and cash equivalents | $(186,394) | $(31,276) |

During the six months ended November 30, 2019 and 2018, cash flows consisted of the following:

#### Cash used in operating activities

Six months ended November 30, 2019:

- Net loss of $4.0 million plus the non-cash items, primarily driven by depreciation and amortization and stock based compensation, contributed to cash used in operations of $0.6 million.
- Working capital was negatively impacted by increased inventory on hand of $10.0 million and decreased accounts payable and accrued liabilities of $8.8 million. Accounts receivable had a favorable impact on working capital as a result of the sale of the Fluid Management business.

Six months ended November 30, 2018:

- Net income was driven by increased sales and increased gross profit. This was partially offset by higher operating expenses in research and development, selling and marketing and general administrative as well as costs related to our acquisition and restructuring activities.
- The Company continues to focus on optimizing its cash conversion cycle. In the second quarter of fiscal year 2019, working capital was negatively impacted by increased inventory on hand of $1.0 million. Additionally, even though days sales outstanding ("DSO") decreased by two days, receivables negatively impacted working capital by $3.1 million as a result of increased sales in the quarter. Also, the $12.5 million DOJ settlement payment that was made during the first quarter of fiscal year 2019 negatively impacted working capital from accounts payable and accrued liabilities.

#### Cash used in investing activities

Six months ended November 30, 2019 and 2018:

- $4.0 million in fixed asset additions versus $1.4 million in the prior year.
- $45.8 million cash payment to acquire Eximo Medical Ltd. in the second quarter of fiscal year 2020 compared to a $37.0 million cash payment to acquire the BioSentry product from SSC and a $47.9 million cash payment to acquire RadiaDyne in fiscal year 2019. Refer to Note 2 to the financial statements.

#### Cash used in financing activities

Six months ended November 30, 2019 and 2018:

- $132.5 million repayment of long-term debt in conjunction with the new Credit Agreement that was entered into at the beginning of the first quarter of fiscal year 2020. Refer to Note 8 of the financial statements.
- $55.0 million draw on the revolver in fiscal year 2019 as a result of the RadiaDyne acquisition described in Note 2 to the financial statements.
- $2.5 million repayment on the Term Loan in the prior year. This was consistent with the required amortization payment on the Term Loan.
- $1.3 million of outlays from stock option and ESPP activity versus $0.9 million in proceeds in the prior year.
- $1.2 million payment on earn-out liabilities in the current year compared to $2.1 million in the prior year.

On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement. The Credit Agreement provides for a $125.0 million secured revolving credit facility, which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.

On December 17, 2019, the Company made a $15.0 million draw on the revolving credit facility as part of the acquisition of the C3 Wave tip location asset from Medical Components Inc. that is described Note 19 to the financial statements. We believe that our current cash and investment balances, together with cash generated from operations and access to our revolving credit facility, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future for cash, we may require external financing.

## Market risk

As filed, 2,734 characters.

### Foreign Currency Exchange Rate Risk

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 7% of our sales in the second quarter of fiscal 2020 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.

### Interest Rate Risk

On June 3, 2019, we entered into the Credit Agreement which provides for a $125 million Revolving Facility. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. In the event of default, the interest rate may be increased by 2.0%.

### Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.

The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.

Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.

## Controls and procedures

As filed, 1,362 characters.

### Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting for the fiscal quarter ended November 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 684 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2019 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Filed Jan 8, 2020.
Source: SEC EDGAR, the filing index for accession 0001275187-20-000005. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
